Targeting the PD-1 may block the suppression of anti-cancer immunity by inhibiting the exhaustion of CD8+ T cells and reverse the dysfunction of tumor-infiltrating lymphocytes in HCC [37]. Here, CD8A is linked to hepatocellular carcinoma.